Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
Expert insights on API manufacturing, CDMO trends, peptide development, and pharmaceutical industry news from Neuland Labs.
PeptidesPeptide manufacturing capacity cannot be determined by equipment size alone, as it depends on molecule-specific characteristics, purification complexity, cumulative yield losses, and process-level constraints rather than simple batch volume metrics.
PeptidesNeuland Labs explores the complexities of peptide API impurity profiling, explaining how structural similarities make detection challenging and outlining orthogonal analytical approaches needed for effective quality control.
PeptidesNeuland Labs successfully manufactured a complex cyclic 16 amino acid peptide API at 100+ kg scale with 98% purity using liquid phase peptide synthesis across 40 optimized stages.
PeptidesA comprehensive guide examining peptide API sourcing strategies in 2026, covering supplier evaluation criteria, capacity constraints from GLP-1 demand, and supply chain resilience in response to regulatory changes like the BIOSECURE Act.
PeptidesExplore how peptide drug development has advanced with secondary structure disruptors and hybrid synthesis methods, enabling complex therapeutics like semaglutide and tirzepatide to reach commercial success in 2026.
PeptidesA guide comparing three peptide synthesis methods, solid phase, liquid phase, and hybrid approaches, to help pharmaceutical programs select the optimal manufacturing strategy based on peptide length, scale, impurity profile, and regulatory timeline.
PeptidesPeptide purification is a complex and costly manufacturing step that separates target peptides from structurally similar impurities, with advanced RP-HPLC techniques offering improved resolution and throughput for challenging molecules.
PeptidesThis article compares three peptide synthesis methods, solid-phase (SPPS), liquid-phase (LPPS), and hybrid approaches, to help developers select the right manufacturing strategy based on peptide length, scale, cost, and timeline.
PeptidesThis article explores key challenges in peptide manufacturing, including synthesis impurities, purification complexity, and scale-up risks, and explains how CDMOs address these obstacles through specialized expertise and infrastructure.
